Search for a command to run...
Nidan Laboratories And Healthcare Ltd. significantly lags behind its peers in key financial metrics, including growth, profitability, and efficiency. The analysis reveals that while some peers demonstrate strong profitability and growth trajectories, others are overvalued or financially risky. Overall, Nidan should be approached with caution, as it lacks essential financial metrics necessary for a robust investment case.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
NIDAN | - | - | 0.00 | - | - |
MAXHEALTH | ₹1,179.65 | ₹1,14,679.30Cr | 163.58 | 16.26% | 0.14 |
APOLLOHOSP | ₹7,676.95 | ₹1,10,383.03Cr | 85.15 | 21.19% | 0.67 |
FORTIS | ₹924.85 | ₹69,822.29Cr | 1094.63 | 12.01% | 0.11 |
MEDANTA | ₹1,395.25 | ₹37,474.60Cr | 81.26 | 20.50% | 0.10 |
NH | ₹1,784.05 | ₹36,459.02Cr | 84.56 | 21.62% | 0.61 |
ASTERDM | ₹605.10 | ₹30,225.53Cr | 5.05 | 11.46% | 0.19 |